2026-01-24 - Analysis Report
**Company Overview:**
Regeneron Pharmaceuticals, Inc. (REGN) is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious diseases.

**Comparison of Return Rates:**

| Ticker | Cumulative Return |
| --- | --- |
| REGN (Review Stock) | 51.09% |
| VOO (Comparison Stock) | 126.41% |
| Divergence (Max: 54.10, Min: -109.60, Current: -75.30, Relative Divergence: 21.00%) | - |

The cumulative return of REGN is 51.09%, which is lower than the cumulative return of VOO (126.41%). The divergence between the two stocks is -75.30, indicating a significant difference in their performance.

**Analysis of Provided Alpha, Beta, and Risk Metrics:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 10.0% | 22.5% | -2.0% | 1.2 | 39.6B |
| 2017-2019 | 11.0% | 27.6% | -15.0% | 1.0 | 39.8B |
| 2018-2020 | 32.0% | 27.6% | 8.0% | 0.7 | 51.2B |
| 2019-2021 | 42.0% | 27.6% | -24.0% | 0.6 | 66.9B |
| 2020-2022 | 75.0% | 25.4% | 68.0% | 0.6 | 76.5B |
| 2021-2023 | 63.0% | 24.4% | 43.0% | 0.6 | 93.1B |
| 2022-2024 | -1.0% | 40.4% | -31.0% | 0.6 | 75.5B |
| 2023-2025 | -18.0% | 57.0% | -93.0% | 0.6 | 81.8B |

The CAGR (Compound Annual Growth Rate) for the 2020-2022 period is 75.0%, indicating a significant increase in the stock's value over this period. The Alpha for the same period is 68.0%, indicating significant outperformance compared to the market.

The Beta for REGN is relatively stable, ranging from 0.7 to 1.2 across different periods. The market capitalization (Cap(B)) has increased significantly over the years, indicating growing investor interest in the stock.

**Recent Stock Price Fluctuations:**

| Metric | Value |
| --- | --- |
| Close | $753.55 |
| Last-Market | $753.55 (-$0.26) |
| 5-day SMA | $745.04 |
| 20-day SMA | $768.45 |
| 60-day SMA | $732.28 |

The stock price has been relatively stable in the short term, with a 5-day SMA of $745.04 and a 20-day SMA of $768.45. The 60-day SMA is lower at $732.28.

**Analysis of RSI, PPO, and Delta Preceding Relative Divergence Metrics:**

| Metric | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.70 |
| RSI | 43.14 |
| PPO | -0.70 |
| Hybrid Signal | Buy (Cash 0%)
Risk Level | Medium (MRI 0.70) |
| Recent (20 days) relative divergence change | 2.10 (+) | 
| 7-day Rank change | 126 (+) | 
| 7-day Dynamic Expected Return change | 57.30 (+) | 

The Market Risk Indicator (MRI) is 0.70, indicating a medium-risk investment. The RSI (Relative Strength Index) is 43.14, indicating overbought conditions. The PPO (Percentage Price Oscillator) is -0.70, indicating a bearish trend.

The hybrid signal is a buy signal with no cash allocation, indicating a cautious approach. The risk level is medium, according to the MRI.

**Recent News & Significant Events:**

See below for news articles.

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 830.04 / 1057.00 / 630.00

**Earnings Analysis:**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |

The recent earnings have been positive, with EPS (Earnings Per Share) increasing in the last quarter. However, revenue growth has been moderate, with a slight dip in the last quarter.

**Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

The profit margin has been relatively stable, ranging from 84.67% to 86.80% across different quarters.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

The equity has increased significantly over the years, indicating growing financial stability. The ROE (Return on Equity) has been moderate, ranging from 2.75% to 4.72%.

**Comprehensive Analysis:**
Regeneron Pharmaceuticals, Inc. (REGN) has shown a relatively stable CAGR (Compound Annual Growth Rate) over the years, with a moderate Beta and a growing market capitalization. The recent earnings have been positive, with a slight dip in the last quarter. The profit margin has been relatively stable, and the ROE has been moderate.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.